

## CASE REPORT

DOI: 10.37047/jos.2023-100694

# Is There Any Relationship Between Bilateral Pleural Effusion and Blast Crisis in Chronic Myeloid Leukemia?

<sup>1</sup>Eylül ERDİNÇ<sup>a</sup>, <sup>2</sup>Musa Barış AYKAN<sup>b</sup>, <sup>3</sup>Mükerrem SAFALI<sup>c</sup>, <sup>4</sup>Fikret ARPACI<sup>d</sup>

<sup>a</sup>Ufuk University Faculty of Medicine, Ankara, Türkiye

<sup>b</sup>Gülhane Training and Research Hospital, Clinic of Medical Oncology, Ankara, Türkiye

<sup>c</sup>Gülhane Training and Research Hospital, Clinic of Pathology, Ankara, Türkiye

<sup>d</sup>Liv Hospital, Clinic of Medical Oncology, Ankara, Türkiye

**ABSTRACT** Pleural effusion in chronic myeloid leukemia (CML) has been rarely reported in medical practice. Additionally, the correlation of pleural effusion with blast crisis is unknown. This study reported a 66-year-old male patient who was diagnosed with bilateral pleural effusion three months before the blast transformation. Bilateral pleural effusion spontaneously resolved before the blast transformation. The cause of pleural effusion was unknown. Bilateral pleural effusion caused by unknown or known factors, except for that induced by drugs, is a poor prognostic marker for CML and is an unusual indicator of blast crisis. The presentation of the study case indicates that bilateral pleural effusion is an atypical and discernible early indicator of blast crisis onset in patients with CML.

**Keywords:** Pleural effusion; chronic myeloid leukemia; blastic transformation

Pleural or peritoneal involvement is rare in leukemias. In contrast, pleural or peritoneal involvement is frequently observed in solid hematological cancers and lymphomas. Pleural effusion may occur in patients with chronic myeloid leukemia (CML).<sup>1,2</sup> The etiological factors for pleural effusion in patients with CML include infections, hypoproteinemia, blast involvement, extramedullary (spleen, lymph nodes, skin, meninges, and bone) hematopoiesis, pleural capillary obstruction, and drugs.<sup>3</sup> Here, we report a case with unusual pleural effusion that manifested three months before the blast crisis of CML. This case report aimed to demonstrate the potential prognostic value of bilateral pleural effusion preceding blast crisis and improve our understanding of this clinical manifestation in CML.

## CASE REPORT

The patient was a 66-year-old male who was initially diagnosed with CML in 1999. An accidental blood test revealed a high leukocyte count when the patient was aged 49 years. Fluorescent in situ hybridization (FISH) analysis revealed that the patient tested positive for BCR-ABL mutation. The patient was initially treated with interferon-alpha. After 3 years, the interferon dosage was reduced to 3 million units due to elevated liver enzymes. Interferon treatment was continued until 2007 because of the complete cytogenetic response. The patient was determined to be in complete cytogenetic remission owing to negative FISH results since the beginning of interferon-alpha therapy. The treatment was

**Correspondence:** Eylül ERDİNÇ  
Ufuk University Faculty of Medicine, Ankara, Türkiye  
**E-mail:** eylul2000erdinc@gmail.com



Peer review under responsibility of Journal of Oncological Sciences.

**Received:** 09 Dec 2023

**Received in revised form:** 11 Jun 2024

**Accepted:** 19 Nov 2024

**Available online:** 04 Dec 2024

2452-3364 / Copyright © 2025 by Turkish Society of Medical Oncology. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

changed to imatinib mesylate (400 mg per day) in 2008 owing to the upregulation of liver enzymes and blood lipids. The patient tested negative in FISH tests up to 2016 and was in complete cytogenetic remission.

In June 2016, the patient was admitted to the hospital with the complaint of left-side pain and the following presentations: fever: 36.5 °C; heart rate: 75/min; blood pressure: 123/70 mmHg. The complete blood count revealed the following findings: hemoglobin: 14.4 g/dL; platelet count: 117,000 platelets/mm<sup>3</sup>; leukocyte count: 6,650 leukocytes/mm<sup>3</sup>. The peripheral blood smear examination was unremarkable. The erythrocyte sedimentation rate was 75 mm/hour. The patient exhibited physiological biochemical parameters. Antibiotic treatment initiated at the hospital did not alleviate the complaints of the patient. Analysis of tuberculosis-causing agents and other bacterial and viral infectious agents did not yield positive results. In the thorax computed tomography scan, pleural effusion was detected on both hemithoraces (9 mm on the right and 30 mm on the left).

No evidence of heart failure was noted. Pleural effusion examination [protein, lactate dehydrogenase (LDH), cell count, differential, and cytology] did not reveal leukemic involvement or other causes. The patient was discharged in August as the complaints improved and the pleural effusion disappeared although weakness persisted (Figure 1).

In October 2016, the patient was hospitalized again with complaints of high fever and fatigue. The

blood count revealed pancytopenia (leukocyte count: 2,200 leukocytes/mm<sup>3</sup>; platelet count: 18×10<sup>3</sup> platelets/mm<sup>3</sup>; hemoglobin: 10 g/dL). Bone marrow biopsy revealed the infiltration of myeloid blast cells.

Morphological and immunohistochemical findings were consistent with the transformation of CML into acute myeloid leukemia (Figure 2). After 1 week, the patient died due to tumor lysis syndrome and acute renal insufficiency (creatinine: 9.1 mg/dL; LDH: 22.970 IU; potassium: 5.5 mmol/L; urea: 389 mg/dL; uric acid: 13.8; Ca<sup>2+</sup>: 8 mg/dL) without leukemia treatment. Informed consent was obtained by the daughter of the patient to publish this case report.

## DISCUSSION

Pleural effusion is a rare finding in both the chronic phase and the acute blast phase of CML. The etiological factors of pleural effusion include leukemic infiltration, extramedullary hematopoiesis, infection, hypoproteinemia, pleural capillary obstruction, leukemic infiltration of the interstitial tissue, and drugs.

The infiltration of leukemia into the pleura typically occurs at the same time as or shortly before the blast crisis phase of bone marrow development.<sup>4</sup> The most common infiltration sites are the brain, testis, skin, breast, soft tissue, synovium, lymph nodes, bones, and the nervous system. However, leukemic infiltration has also been reported in the gastrointestinal tract, ovaries, kidneys, and pleura. Pleural involvement is rare. Isolated pleural blast crises without medullary change are extremely uncommon.<sup>5</sup> In the




FIGURE 1: Computed tomography scan of the thorax revealed that pleural effusion spontaneously resolved after three months.




FIGURE 2: Diffuse myeloid blast cell infiltration in the bone marrow (H&E,  $\times 100$ ). IHC analysis of CD34+ blast cells (magnification:  $\times 100$ ).

study patient, pleural blast infiltration was not observed in the chronic and blast phases.

Extramedullary hematopoiesis is also a potential cause of pleural effusion in CML. In contrast to pleural leukemic infiltration, extramedullary hematopoiesis involves hematopoietic cells of the erythroid, myeloid, and megakaryocytic types. The study case did not exhibit extramedullary hematopoiesis.

Infection and hypoproteinemia are proposed as non-cancerous causes of effusion.<sup>2</sup> The study case did not exhibit hypoproteinemia or any other infection.

Cytokine production-induced uncontrolled leukocytosis and enhanced capillary permeability may cause pleural capillary blockage or leukemic cell invasion into the interstitial tissue, leading to the development of pleural effusions in patients with CML.<sup>4</sup> In patients with myeloproliferative disease, the upregulated levels of interleukin (IL)-8, IL-2R, IL-12, IL-15, and IP-10 were independent predictors of poor survival.<sup>6</sup> Similar cytokine profiles have been reported during chimeric antigen receptor T-cell therapy and the infusion of hypercellular leukapheresis products.<sup>7</sup> Leukostasis and platelet dysfunction are predisposing factors for hemorrhagic effusion in CML. The study patient did not exhibit leukocytosis during pleural effusion.

Drugs can also induce pleural effusion in CML. Dasatinib and imatinib, which are tyrosine kinase inhibitors (TKIs), are used to treat CML. TKIs can induce pleural effusion.<sup>8</sup> The pathophysiology of dasatinib-induced pleural effusion has not been elucidated, although TKIs were reported to exert off-target effects on the immune system.<sup>9</sup> The study patient underwent imatinib treatment, but the pleural effu-

sion resolved spontaneously despite the non-cessation of imatinib.

Thus, pleural effusion in the study case, which started in June, was resolved in August. One potential reason for pleural effusion is an unknown infectious agent. Unknown causes and cytokines released before blast transformation can also cause pleural effusion. Bilateral pleural effusion caused by known or unknown factors, except that caused by drugs, is a poor prognostic marker in patients with CML and an unusual indicator of blast crisis.

#### Source of Finance

*During this study, no financial or spiritual support was received neither from any pharmaceutical company that has a direct connection with the research subject, nor from a company that provides or produces medical instruments and materials which may negatively affect the evaluation process of this study.*

#### Conflict of Interest

*No conflicts of interest between the authors and / or family members of the scientific and medical committee members or members of the potential conflicts of interest, counseling, expertise, working conditions, share holding and similar situations in any firm.*

#### Authorship Contributions

**Idea/Concept:** Eylül Erdinç, Fikret Arpacı; **Design:** Eylül Erdinç, Fikret Arpacı; **Control/Supervision:** Eylül Erdinç, Fikret Arpacı; **Data Collection and/or Processing:** Fikret Arpacı, Musa Barış Aykan, Mükerrerem Safalı; **Analysis and/or Interpretation:** Eylül Erdinç, Fikret Arpacı; **Literature Review:** Eylül Erdinç, Fikret Arpacı; **Writing the Article:** Eylül Erdinç, Fikret Arpacı, Mükerrerem Safalı; **Critical Review:** Eylül Erdinç, Fikret Arpacı, Musa Barış Aykan, Mükerrerem Safalı; **References and Fundings:** Fikret Arpacı; **Materials:** Fikret Arpacı.

---

## REFERENCES

1. Kaur H, Kaur P, Singla V. A case of chronic myeloid leukemia with unusual presentation. *Research*. May 2014;1:781. [https://www.researchgate.net/publication/273095897\\_A\\_case\\_of\\_chronic\\_myeloid\\_leukemia\\_with\\_unusual\\_presentation](https://www.researchgate.net/publication/273095897_A_case_of_chronic_myeloid_leukemia_with_unusual_presentation)
2. Aleem A, Siddiqui N. Chronic myeloid leukemia presenting with extramedullary disease as massive ascites responding to imatinib mesylate. *Leuk Lymphoma*. 2005;46(7):1097-1099. PMID: 16019565.
3. Nuwal P, Dixit R, Dargar P, George J. Pleural effusion as the initial manifestation of chronic myeloid leukemia: Report of a case with clinical and cytologic correlation. *J Cytol*. 2012;29(2):152-154. PMID: 22787303; PMCID: PMC3391803.
4. Gao X, Li J, Wang L, et al. Bilineal extramedullary blast crisis as an initial presentation of chronic myeloid leukemia: a case report and literature review. *Am J Case Rep*. 2016;17:793-798. PMID: 27784881; PMCID: PMC5085336.
5. Das U, Gupta VK, Nyandak T, et al. Pleural involvement in chronic myelocytic leukaemia-an extra-medullary blast crisis. *J Indian Academy Clin Med*. 2010;11(4):326-329. [https://www.researchgate.net/publication/280318569\\_Pleural\\_Involvement\\_in\\_Chronic\\_Myelocytic\\_Leukaemia\\_-\\_an\\_Extra-medullary\\_Blast\\_Crisis](https://www.researchgate.net/publication/280318569_Pleural_Involvement_in_Chronic_Myelocytic_Leukaemia_-_an_Extra-medullary_Blast_Crisis)
6. Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. *J Clin Oncol*. 2016;34(20):2333-2340. PMID: 27217448; PMCID: PMC5118045.
7. Alter A, Chaisson N, Mukherjee S, Gildea T. A 68-year-old man with chronic myelogenous leukemia and a large unilateral pleural effusion. *Chest*. 2018;153(2):e33-e36. PMID: 29406237.
8. Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. *J Clin Oncol*. 2011;29(10):1356-1363. PMID: 21300928.
9. Mata M, Gerken C, Nguyen P, Krenciute G, Spencer DM, Gottschalk S. Inducible activation of MyD88 and CD40 in CAR T cells results in controllable and potent antitumor activity in preclinical solid tumor models. *Cancer Discov*. 2017;7(11):1306-1319. PMID: 28801306; PMCID: PMC5780189.

ARTICLE IN PRESS